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Abstract
Drug distribution in cells is a fundamentally important, yet often overlooked, variable in drug efficacy. Many weakly basic
anticancer agents accumulate extensively in the acidic lysosomes of normal cells through ion trapping. Lysosomal trapping
reduces the activity of anticancer drugs, since anticancer drug targets are often localized in the cell cytosol or nucleus. Some
cancer cells have defective acidification of lysosomes, which causes a redistribution of trapped drugs from the lysosomes to
the cytosol. We have previously established that such differences in drug localization between normal and cancer cells can
contribute to the apparent selectivity of weakly basic drugs to cancer cells in vitro. In this work, we tested whether this
intracellular distribution-based drug selectivity could be optimized based on the acid dissociation constant (pKa) of the
drug, which is one of the determinants of lysosomal sequestration capacity. We synthesized seven weakly basic structural
analogs of the Hsp90 inhibitor geldanamycin (GDA) with pKa values ranging from 5 to 12. The selectivity of each analog was
expressed by taking ratios of anti-proliferative IC50 values of the inhibitors in normal fibroblasts to the IC50 values in human
leukemic HL-60 cells. Similar selectivity assessments were performed in a pair of cancer cell lines that differed in lysosomal
pH as a result of siRNA-mediated alteration of vacuolar proton ATPase subunit expression. Optimal selectivity was observed
for analogs with pKa values near 8. Similar trends were observed with commercial anticancer agents with varying weakly
basic pKa values. These evaluations advance our understanding of how weakly basic properties can be optimized to achieve
maximum anticancer drug selectivity towards cancer cells with defective lysosomal acidification in vitro. Additional in vivo
studies are needed to examine the utility of this approach for enhancing selectivity.
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Introduction
Many anti-cancer drugs suffer from poor selectivity to target
cells, leading to a high degree of toxicity and potentially life-
threatening side effects; therefore, chemotherapy is often prema-
turely stopped, reducing the chances of a drug achieving its full
potential. Anti-cancer drugs typically possess some degree of
intrinsic selectivity towards cancer cells due to biochemical and/or
metabolic differences between normal and transformed cells [1–3].
The intrinsic selectivity of an anticancer agent can be further
enhanced using a variety of drug delivery approaches based on
Ehrlich’s proposed ‘‘magic bullet’’ [4,5]. All of these targeting
strategies share a common requirement, which is that the active
cytotoxic agent must accumulate to a greater extent in or around
transformed cells relative to normal cells. Although numerous
creative strategies have been examined, such as prodrug strategies
and antibody-drug conjugates, their therapeutic usefulness has
been somewhat limited [6].
The intracellular distribution of a drug is a fundamentally
important consideration for drug efficacy. Mammalian cells are
extensively compartmentalized, and both drugs and their targets
can have specific and discrete intracellular localization patterns.
Accordingly, for the intended therapeutic effect to occur, the
intracellular site of drug localization must be the same, to a certain
degree, as that of the drug target. We and others have previously
shown that physicochemical properties of drugs can predictably
influence their intracellular localization pattern [7–10]. In
addition, we have shown that a single drug can have substantially
different intracellular localization and trafficking patterns in
different cell types [11,12].
The purposeful targeting of anticancer drugs to intracellular
compartments in cancer cells represents an emerging area of
exploration [13,14]. For example, mitochondria have a negative
membrane potential associated with their inner membrane, which
has been shown to drive the accumulation of drugs with
delocalized cationic charge [15]. In this regard, derivatives of
Hsp90 inhibitors have been developed to exploit this finding and
therefore selectively target a mitochondrial form of Hsp90 [16].
Alternatively, many weakly basic drugs with localized cationic
charges have been shown to be extensively sequestered in acidic
lysosomes of cells through an ion trapping mechanism, and the
properties of the cell and drug that influence this have been
reviewed [17]. Briefly, the pH of the lysosomes, relative to the pH
of the cytosol, is one of the key physiological parameters that
dictates the predicted degree of lysosomal accumulation [12,17].
The greater the lysosome-to-cytosol pH gradient, the greater the
extent of lysosomal sequestration is. For many amines, lysosomal
trapping has been shown to be quite extensive, and is thought to
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approximate the total cellular accumulation [18]. Since drug
targets are seldom localized in lysosomes, the extensive trapping of
weak bases in this compartment can greatly reduce target
interactions, thereby reducing drug activity.
Interestingly, we and others have shown that several cancer cell
types have a lysosomal acidification defect [19–22]. In some
instances, the lysosomal pH of cancer cells has been reported to be
2 pH units higher than the lysosomal pH of normal cells [22]. This
elevation in lysosomal pH is predicted to have a profound impact
on the intracellular distribution of weakly basic amines that are
substrates for ion trapping in lysosomes (lysosomotropic agents).
Specifically, the concentration of such drugs will decrease in the
lysosomes of such cells and concomitantly increase in the cytosol as
well as in other extralysosomal compartments. We propose that
this difference in drug distribution behavior will facilitate an
enhancement in drug activity in cancer cells relative to normal
cells.
We have previously established the basis for this intracellular
distribution-based drug (IDB) targeting platform using both in vitro
and in vivo approaches [12,23,24]. Using cells grown in culture, we
quantitatively measured the lysosome-to-cytosol concentration
ratios of drugs in cells with low or elevated lysosomal pH. Weakly
basic anticancer drugs were shown to redistribute from the
lysosomes to the cytosol when lysosomal pH was elevated. This
intracellular redistribution of drugs resulted in more pronounced
cytotoxicity toward cells with elevated lysosomal pH. Importantly,
such changes in intracellular distribution and toxicity were not
observed for anticancer drugs without lysosomotropic properties.
More recently, we established the basis for the IDB targeting
platform in mice by evaluating the degree of drug-induced toxicity
in mice with low or experimentally elevated lysosomal pH [24].
In this report we specifically questioned whether the lysosomo-
tropic potential of a cancer drug correlated with the degree of IDB
selectivity. This is a very important consideration that could guide
the rational design of new anticancer agents with properties that
optimize lysosomotropism and therefore IDB selectivity, or the
modification of existing drugs to impart these properties.
Results
Selection and synthesis of analogs of geldanamycin with
a range of weakly basic pKa values
We have previously shown that weakly basic anticancer drugs
with lysosomotropic properties exhibit greater selectivity toward
cancer cells than do their non-lysosomotropic counterparts [12].
In the present work, we tested the prediction that the lysosomo-
tropic potential of weakly basic drugs correlates with their degree
of differential selectivity toward cancer cells.
In addressing this question, we considered the drug-associated
factors that are known to contribute to lysosomotropism. All
substrates for ion trapping-based lysosomotropism are weakly
basic, but not all weakly basic molecules are lysosomotropic. In his
commentary on the subject, de Duve proposed that two
independent drug-associated properties influence the lysosomo-
tropic potential of a given drug. The first parameter is termed
alpha and represents the lysosomal membrane permeability ratio
for the drug in its ionized versus unionized forms. We have
previously experimentally estimated alpha for a number of
compounds by measuring octanol/buffer partition coefficients as
a function of pH and correlated these values with lysosomal
sequestration [7]. The second important drug-associated param-
eter is the pKa of the conjugate acid of the base. We have
previously experimentally established how pKa of drugs influence
lysosomal sequestration in cultured cells [8].
In this work, we chose to evaluate the influence of pKa on
selectivity using inhibitors of the 0 kD heat shock protein (Hsp90)
that systematically varied in their weak base pKa. We chose to
modify the 17-position of the Hsp90 inhibitor GDA to create
derivatives with varied pKa since previous reports had shown that
modifications to this position did not alter activity [25].
To help guide our selection of derivatives with varying pKa, we
considered a previously described theoretical relationship between
weak base pKa and alpha on the lysosome-to-extracellular
concentration ratio [17], which is given by the following
expression.
½lysosome
½extracellular~
a Hz½ EzKa
 
Hz½ EzKa
 
Hz½ LzKa
 
a Hz½ LzKa
 
The conjugate acid of weak base dissociation constant is
denoted as Ka, and [H
+] denotes the proton concentrations
(subscript E represents extracellular and subscript L represents
lysosomal). The term alpha (a) denotes the ratio of lysosomal
membrane permeabilities for the ionized base divided by that of
the un-ionized species [26]. Using this equation, we calculated the
theoretical lysosome-to-extracellular concentration ratio of a series
of drugs with pKa values ranging from 4 to 14. For the
calculations, we used lysosomal and extracellular pH values of
4.4 and 7.4, respectively, which are typical values for normal cells
[27], and an alpha value of 0.01, which we had previously
measured for 17-DMAG, a weakly basic derivative of GDA [12].
To demonstrate the potential influence of alpha on lysosomal
sequestration, we have included plots in which this parameter is
varied. Plotting the predicted lysosome-to-extracellular concentra-
tion ratios against pKa gave a bell-shaped curve, whereby the
maximum degree of lysosomal sequestration and the pKa at which
this occurred were sensitive to the magnitude of the alpha
parameter (see Figure 1). Based on these simulations, we
postulated that anticancer agents that vary in pKa from
approximately 5 to 12 would adequately characterize the influence
of lysosomal sequestration on tumor selectivity.
We therefore synthesized a number of weakly basic analogs of
GDA in an attempt to develop of small set of derivatives that had
Figure 1. Theoretical plot of lysosomal sequestration as a
function of weak base pKa and alpha (a). The equation used for
these simulations can be found in the text. The pH of lysosomes and
extracellular space were set at 4.4 and 7.4, respectively. The alpha
parameter was varied as indicated.
doi:10.1371/journal.pone.0049366.g001
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pKa values spanning this range. The GDA derivatives were
synthesized as described in Materials and Methods and charac-
terized by 1H-NMR (see Text S1). The pKa values for analogs 1,
2, 3, 5 and 6 (see Figure 2 for chemical structures) were measured
at 37uC using 1H NMR. To determine the pKa using this method,
the chemical shifts of protons alpha to the ionizable amine were
plotted against pH, yielding sigmoidal curves (Figure S1) from
which pKa was derived. For compounds 4 and 7, pKa could not
be measured by 1H NMR due to either limited solubility in D2O
and/or poorly resolved proton peaks. Therefore, we report a
previously measured pKa value for compound 4 that was procured
using an alternative approach [12], and we report a calculated
value for compound 7 (see Materials and Methods). Compound 5
had two pKa values of 9.9 and 4.2. Only the higher pKa value is
reported in Figure 2 because the second is too low to theoretically
contribute to ion trapping in lysosomes. Collectively, the pKa
values for each of the derivatives ranged from 5.8 to 12.4 (Figure 2).
To appropriately test the influence of weak base pKa on
selectivity, all derivatives of GDA should retain some capacity to
bind Hsp90 and act as inhibitors. To assess this, we evaluated the
binding affinity of each of the derivatives to recombinant Hsp90
and compared the binding affinity with that of unmodified GDA.
Binding affinities were estimated using a fluorescence polarization
assay that measures the ability of test compounds to competitively
displace FITC-conjugated GDA from Hsp90. The polarization
(mP) values were converted to percent of control (no drug) and
plotted against the concentration of test compounds, yielding
sigmoidal curves from which the IC50 value was determined
through curve fitting (Figure S2). The Ki values were calculated
from IC50 values as previously described [28] using an online
calculator (freely available at http://sw16.im.med.umich.edu/
software/calc_ki/). The calculated IC50 for underivatized GDA
was 230 nM, which is similar to previously reported values
obtained using this assay [29]. A comparison of Ki values for GDA
and its derivatives suggests that they all retain some capacity to
bind Hsp90 and are therefore suitable for the evaluations
described here (Figure 2).
Assessment of intracellular distribution-based selectivity
To quantitatively express selectivity, we comparatively evaluat-
ed antiproliferative IC50 values in normal and cancer cells that had
low and elevated lysosomal pH, respectively. For these evaluations,
we utilized the HL60 human leukemic cell line, which we have
previously shown to have an elevated lysosomal pH [22]. For the
non-transformed cells, we utilized normal human foreskin
fibroblasts that had previously been determined to have a
lysosomal pH of 4.4 [22]. The cytotoxicity curves and IC50 values
obtained from them are shown in Figure S3. By dividing the IC50
determined in normal cells by the IC50 in cancer cells, we obtained
the overall selectivity (Figure 3). The non-lysosomotropic inhibitor
GDA had an overall selectivity near two, which indicates that
GDA was nearly twice as active in the leukemic cell line as it was
in the normal cells. Interestingly, weakly basic inhibitors with pKa
values near 8 had several-fold greater activity in the leukemic cells
with elevated lysosomal pH compared to normal cells. Analogs of
GDA that had pKa values far above or below 8 had no apparent
increase in selectivity towards the cancer cells compared to
underivatized GDA. On the whole, the influence of pKa on
selectivity tended to yield a bell-shaped distribution that was
Figure 2. Structures and properties of geldanamycin deriva-
tives. The seven derivatives with different weak base modifications at
the 17-position of GDA are shown. The pKa values for derivatives 1, 2, 3,
5 and 6 was measured experimentally using proton NMR (n = 1). The
pKa for compound 4 was measured experimentally in an earlier
manuscript (see Results). The pKa for compound 7 was estimated using
software (see Materials and Methods). The binding affinity for each of
the inhibitors with rHsp90 is shown (n = 2), and was based on a
previously established fluorescence polarization assay (see Materials
and Methods).
doi:10.1371/journal.pone.0049366.g002
Figure 3. Overall selectivity comparisons for geldanamycin and
its derivatives with varying pKa. Overall selectivity represents the
IC50 for a derivative in normal human fibroblasts divided by the value
obtained in HL60 human leukemic cells. Bars represent mean6s.d.
(n = 3); *, p,0.05 compared to GDA.
doi:10.1371/journal.pone.0049366.g003
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similar to the theoretical plot correlating pKa with lysosomotrop-
ism (Figure 1).
Selectivity is multifactorial, and any successful cancer drug
should exhibit greater activity toward cancer cells relative to
normal cells through mechanisms that are unrelated to changes in
intracellular distribution behavior that are evaluated in this
manuscript [2,3]. To directly the examine the selectivity that
can be specifically attributed to changes in intracellular distribu-
tion behavior between normal and transformed cells, we
considered it imperative to compare the antiproliferative activity
of a given drug in two cell lines that are otherwise identical but
have low (normal) and elevated (cancer-like) lysosomal pH. This
approach would be most desirable because any inter-cell
variability in factors that can influence drug activity (e.g.,
expression of drug efflux transporters) would be mitigated.
Although many cancer cell lines have been shown to have
defective acidification of lysosomes, we found that a number of
them maintain normally acidified lysosomes. For example, the
MDA-MB-231 breast adenocarcinoma cell line maintains a
lysosomal pH of 4.2, similar to the lysosomal pH of most normal
cells [27]. Using this cell line, we explored an siRNA approach to
transiently elevate lysosomal pH. Lysosomal pH is regulated by the
vacuolar proton ATPase (V-H+-ATPase) [30], and Lu and
coworkers have previously shown that reducing the expression of
a subunit of this enzyme, using siRNA, yielded cells with altered
V-ATPase proton pumping activity, with no effect on cell
proliferation [31]. We utilized a similar technique to create
MDA-MB-231 cells with elevated lysosomal pH. Specifically, we
targeted the V1E1 subunit of V-ATPase for knockdown using
lentiviral vector shRNA. The lentiviral-mediated transfer was
chosen because this approach allows for efficient, high-throughput
and stable knockdown of target proteins [30]. MDA-MB-231 cells
that were treated with lentiviral particles containing non-target
(scrambled) sequence shRNA retained low lysosomal pH and
served as an important control for any non-specific effects of the
lentiviral infection on cell viability. Knockdown of V1E1
expression in cells receiving target viral particles was confirmed
using Western blot analysis (Figure 4A). Importantly, knockdown
of the V1E1 subunit led to no discernible effects on the growth of
cells over the time course of the IC50 evaluations (Figure 4B).
Experimental evaluation of lysosomal pH after knocking down the
V-H+-ATPase subunit showed that lysosomal pH was significantly
elevated from pH 4.4 to pH 5.8 (Figure 4A).
We subsequently evaluated the IC50 of the Hsp90 inhibitors in
both cell types (Figure S4) and calculated selectivity as IC50 in
MDA-MB-231 cells with low lysosomal pH divided by IC50 in
MDA-MB-231 cells with elevated lysosomal pH. Consistent with
our expectations, the activity of non-lysosomotropic GDA was not
Figure 4. Characterization of MDA-MB-231 cells with reduced V-H+-ATPase subunit V1E1 expression and increased lysosomal pH. A.
Western blot analysis of the V1E1 subunit expression is shown along with the actin loading control. Experimentally determined lysosomal pH values
in untreated, scrambled shRNA- and V1E1 shRNA-treated cells is shown (values represent the mean6s.d., n = 3) B. V-ATPase subunit knockdown does
not alter the growth rate of MDA-MB 231 cells. The filled circles represent cells treated with the scrambled shRNA vector and the open circles
represent cells treated with the V-ATPase V1E1 shRNA. Cells were plated at a density of 36105 cells/well on a 6-well plate and were trypsinized,
counted and replated every 24 hours for 3 days (data points represent the mean6s.d, n = 3).
doi:10.1371/journal.pone.0049366.g004
Figure 5. Intracellular distribution-based drug selectivity
comparisons for geldanamycin and its derivatives with varying
pKa. IDB selectivity is defined as the IC50 in MD-MB-231 cells treated
with scrambled shRNA, which have low lysosomal pH, divided by the
value obtained from the same cell line treated with shRNA against the
V1E1 subunit of the vacuolar proton ATPase, which have elevated
lysosomal pH. Bars represent mean6s.d. (n = 3); *, p,0.05 compared to
GDA.
doi:10.1371/journal.pone.0049366.g005
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influenced by the lysosomal pH status of the cell and therefore had
no apparent IDB selectivity (i.e., IDB selectivity value near one,
see Figure 5). The trends in IDB selectivity as a function of Hsp90
inhibitor pKa followed a similar bell-shaped profile as did the
overall selectivity results shown in Figure 3. Moreover, compar-
isons of the magnitude of the IDB with overall selectivity suggest
that IDB selectivity is a major contributing factor to the overall
selectivity of these agents.
Our previous results are consistent with the notion that Hsp90
inhibitors with optimal lysosomotropic properties (i.e., pKa values
near 8) will possess the greatest degree of IDB selectivity toward
transformed cells. To further evaluate this, we evaluated the IDB
selectivity of additional classes of anticancer agents that do or do
not possess lysosomotropic properties.
Mitoxantrone and daunorubicin are weakly basic anticancer
agents that have nuclear targets and pKa values near 8 [32], which
should promote lysosomotropism and IDB selectivity. Alternative-
ly, the antimetabolite 5-fluorouracil is weakly acidic, with a pKa of
8 [33], and is thus not considered a substrate for ion trapping in
acidic lysosomes. 5-Fluorouracil should therefore neither have
intracellular distribution nor activity that is influenced by the
lysosomal pH status of a cell. Similarly, anticancer agents that are
zwitterionic, with both weakly acidic and weakly basic groups,
such as chlorambucil [34], are not lysosomotropic and should not
exhibit IDB selectivity. Consistent with our reasoning, the non-
lysosomotropic anticancer agents 5-fluorouracil and chlorambucil
had IDB selectivity values near one, similar to GDA (Figure 6).
Alternatively, the lysosomotropic agents mitoxantrone and dau-
norubicin both showed significant but different degrees of IDB
selectivity (Figure 6). The cytotoxicity curves for these evaluations
are shown in Figure S5.
Discussion
In this study we have, for the first time, systematically
investigated how the pKa of weakly basic anticancer agents
influences the degree of IDB selectivity toward cancer cells with
elevated lysosomal pH. We propose that the IDB drug targeting
platform presents a paradigm shift in the approach of designing
new anticancer agents with enhanced and optimized selectivity
toward tumor cells. Traditional SAR approaches for enhancing
selectivity focus mainly on designing drugs with greater potency
against cancer cells, with little attention paid to the activity of the
drug in normal cells. Most drug delivery-based approaches that
attempt to increase selectivity rely on tumor-specific drug
accumulation/delivery, which has proven to be quite challenging
and difficult to attain. The IDB drug targeting approach described
here allows the drug to distribute equally to both normal and
transformed cells; however, the drug therapeutic index is widened
by purposefully designing the drug to have unfavorable intracel-
lular distribution properties in normal cells, thus reducing drug
activity in these cells.
Our previous study had established that lysosomotropic
molecules had measurable IDB selectivity, but it remained unclear
whether the degree of lysosomotropism correlated with the degree
of IDB selectivity. Our hypothesis leading into this study was that
anticancer agents with optimal lysosomotropic properties would
have optimal IDB selectivity. We initially utilized ion trapping
principles to theoretically establish the relationships between weak
base properties of drugs, specifically permeability (alpha) and pKa,
and lysosomal sequestration (see Figure 1). These calculations were
revealing and suggested that weakly basic molecules with low
alpha and pKa near or above neutrality would have optimal
lysosomotropic properties.
Our theoretical predictions illustrate that the alpha permeability
parameter represents an important predictor of lysosomal
sequestration; however, it is not a physical parameter that can
be rationally and systematically changed to test the relationship
between lysosomotropism and IDB selectivity. We have previously
experimentally estimated alpha by measuring octanol/water
partition coefficients as a function of pH and found that molecules
either tended to have alpha parameters near zero or near one [7].
Although alpha can vary from zero to one, our theoretical
predictions revealed that relatively small changes in the values of
alpha near zero had a profound impact on the relationship
between weak base pKa and the magnitude of lysosomal
sequestration (Figure 1). It is currently unclear what structural
characteristics might be responsible for such minor perturbations
in the alpha parameter (i.e., 0.01 versus 0.001).
Unlike the alpha parameter, pKa represents a physical property
that can be rationally modified to test the relationship between
lysosomotropism and selectivity. To systematically investigate the
influence of weak base pKa on IDB selectivity, we synthesized a
small library of analogs of GDA generated by modifying GDA at
the 17-position. These GDA analogs were particularly well-suited
for such an application because numerous analogs formed by
synthetic modifications at this position have been shown to retain
their ability to bind with and inhibit Hsp90 [25]. In addition,
GDA has a cytosolic target, and therefore, the activity of GDA
analogs should be sensitive to changes in lysosomal sequestration.
We synthesized weakly basic analogs of GDA with pKa values that
varied from 5.8 to 12.4, and we observed that they all appeared to
retain some capacity to bind rHsp90 as unmodified GDA
(Figure 2). It is important to note that differences in intrinsic
Hsp90 binding affinity among the various derivatives may indeed
influence the magnitude of an experimentally observed IC50 value
in a single cell line; however, these differences should not
theoretically influence our selectivity comparisons presented in
Figures 3 and 5. This is because we report the ratio of IC50 values
for a single drug in cells with low or elevated lysosomal pH, thus
Figure 6. Only lysosomotropic anticancer agents possess
significant intracellular distribution-based drug selectivity.
Mitoxantrone and daunorubicin are weakly basic with pKa values near
8 and have significant IDB selectivity. Non-lysosomotropic anticancer
agents 5-fluorouracil and chlorambucil have IDB selectivity values near
1, which demonstrates that their activity is not influenced by lysosomal
pH. Bars represent mean6s.d. (n = 3).
doi:10.1371/journal.pone.0049366.g006
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factoring out any differences in intrinsic activity that may be
present.
Use of shRNA to create variants of the MDA-MB-231 cell lines
that differed in lysosomal pH represents a valuable tool to directly
test IDB selectivity. In our previously published evaluations, we
utilized comparative IC50 evaluations in two different cell lines
with low or elevated lysosomal pH [12]. In addition, we utilized a
pharmacological modulator of lysosomal pH (i.e., ammonium
chloride) to achieve lysosomal pH elevation. Both of these
approaches have limitations because the differences in cytotoxicity
could be attributed to the differences in cell lines or to the addition
of the pH modifier and not specifically to the differences in
lysosomal pH.
The GDA analog with a measured pKa of 8.1 was found to
have the maximum degree of IDB selectivity. GDA analogs with
pKa values well above or below 8 showed minimal selectivity,
which is consistent with the notion that lysosomotropic potential
correlates with IDB selectivity. To assess the overall selectivity of
the GDA analogs, we compared the ratio of IC50 values in normal
fibroblasts versus in HL-60 leukemic cells, which have been shown
to have elevated lysosomal pH [22]. Interestingly, the trend in the
overall selectivity of the GDA analogs was similar in appearance
and magnitude with the IDB selectivity results. This finding
suggests that IDB selectivity can represent a major contributing
factor towards overall selectivity.
To further evaluate the influence of lysosomotropism on IDB
selectivity, we probed the correlation using currently available
anticancer agents that had different structures, intracellular targets
and mechanisms of action from those of the previously evaluated
Hsp90 inhibitors (Figure 5). Consistent with our hypothesis, the
non-lysosomotropic anticancer agents 5-fluorouracil and chloram-
bucil did not show appreciable IDB selectivity. In contrast, weakly
basic anticancer agents with pKa values near 8 were found to
possess IDB selectivity. Specifically, the weakly basic drugs
mitoxantrone and daunorubicin, which have pKa values of 8.1
and 8.4, respectively, were both found to possess significant
degrees of IDB selectivity. It is interesting to note that
daunorubicin had a significantly higher IDB selectivity than did
mitoxantrone. This could be attributed to the fact that the pKa of
daunorubicin is slightly higher than the pKa of mitoxantrone and
that relatively minor changes in pKa can translate into fairly
significant increases in IDB selectivity. It is also plausible that there
could be slight variations in the alpha permeability parameter for
these two compounds that could result in dramatic alterations in
lysosomotropism as was theoretically determined (Figure 1). In
addition to these drugs, numerous other clinically approved
anticancer agents can be classified as weakly basic molecules. To
our knowledge, there is currently no clinical evidence to support
the notion that their weakly basic properties contributes to their
observed selectivity.
It is important to emphasize that the IDB drug targeting
platform described here will not be universally applicable to all
cancer types. An obvious prerequisite to the successful application
is that the cancer cells have a lysosomal acidification defect. We
and others have shown that many different cancer cell types have
defective lysosomal pH [19–22]; however, as we have illustrated in
this manuscript, some cancer cells, such as the MBA-MB-231 cell
line, have lysosomal pH values that are similar to those in normal
cells. In addition, some work has suggested that the emergence of
drug resistance of cancer cells is associated with the re-acidification
of lysosomes [35]. More work will be needed to identify the
prevalence and mechanism of defective acidification in primary
human tumors.
Another important consideration regarding the potential
applicability of the IDB targeting platform is the pH of the tumor
microenvironment. In most solid tumors, the extracellular pH can
be quite acidic [36]. This might also be the case for leukemic stem
cells localized in hypoxic niches in the bone marrow. Anticancer
agents with pKa values near 8 will be more extensively ionized in
the extracellular fluid surrounding such tumor cells than in the
extracellular fluid surrounding normal cells. Such differences in
extracellular ionization could reduce the kinetics of accumulation
of weakly basic drugs in tumor cells compared to normal cells and
partially or fully offset any benefits derived from IDB selectivity.
However, hematological cancers as well as circulating metastatic
malignancies would not experience such extracellular acidification.
Accordingly, the results of this work may be most applicable to
such freely circulating cancer cells. Future examinations with
additional cancer cell types (i.e., metastatic malignancies) with
variation in the extracellular pH of the cell culture media might
further define the limitations and applicability of this approach to
enhancing selectivity.
In conclusion, we propose that the findings reported in this
study have significant implications toward the rational synthesis of
new drugs that have optimized selectivity toward transformed cells
or the modification of existing drugs. Specifically, our results
suggest that medicinal chemistry-based efforts that promote
lysosomotropism of anticancer agents might increase their
therapeutic index. However, there are potential downsides
associated with the development of highly lysosomotropic drugs
that need to be considered and could not be fully explored using
our cell culture-based evaluations. Specifically, several cationic
amphiphillic drugs that extensively accumulate within lysosomes
have been shown to cause a lysosomal phospholipidosis in vivo,
potentially through their inhibition of lysosomal phospholipases
[37]. The long-term toxicological implications of drug-induced
phospholipidosis, if any, remain to be elucidated. In addition, it is
possible that imparting lysosomotropic properties might negatively
impact other pharmacokinetic attributes and/or the propensity for
off-target interactions unrelated to lysosomal sequestration.
Medicinal chemists involved in early drug discovery strive to
optimize the structural and physicochemical properties of drugs to
promote high affinity interactions with intended targets and to
make the candidate possess ‘‘drug-like’’ properties to minimize
attrition during the various stages of development [38–40]. Such
failures are often attributed to poor ADMET (absorption,
metabolism, metabolism, elimination and transport) properties
and/or unacceptable toxicity profiles [41]. Accordingly, one must
recognize that optimization of basicity may be beneficial for
selectivity, as proposed here, but such alterations may adversely
impact other important attributes that could potentially cause
failure. Ultimately, a holistic approach is required to develop a
successful drug.
Materials and Methods
Cell lines and cell culture reagents
HL-60 cells were kindly provided by Dr. Yuesheng Zhang and
were propagated as described [42]. Normal human fibroblasts
(CRL-2076), MDA-MB-231 (HTB-26) human breast adenocarci-
noma cells and HEK 293T cells were obtained from the American
Type Culture Collection (Rockland, MD) and were propagated
according to the supplier’s guidelines. All cells were maintained at
37uC in a humidified incubator supplied with 5% CO2, and the
cells were passaged for up to 2 months.
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Synthesis of geldanamycin analogs varying in pKa
Geldanamycin was obtained from LC Labs (Woburn, MA). All
other chemicals were obtained from Sigma Aldrich (St. Louis,
MO) or Alfa Aesar (Ward Hill, MA) and were used as received.
DMF was freshly distilled and dried over a 3Å molecular sieve
before use. The following synthetic methods were followed:
Synthetic method A. To a solution of GDA (1 eq. in DMF)
was added the corresponding amine (2 eq.) dissolved in DMF, and
the mixture was stirred at room temperature for 24 h in the dark.
Afterwards, the reaction mixture was diluted with water and
washed three times with chloroform. The organic layers were
combined and dried over anhydrous Na2SO4. The solvent was
then removed under reduced pressure, and the crude product was
purified by flash chromatography with silica using methanol/
chloroform as eluent.
Synthetic method B. Sodium (10 eq. of 60% w/w in mineral
oil) was added to the corresponding amine (5 eq.) dissolved in
DMF. The mixture was stirred at room temperature under argon
for 20 min, followed by the addition of GDA (1 eq.) in DMF. After
24 h, DMF was removed under reduced pressure, and the crude
product was purified by recrystallization from methanol/chloro-
form.
The GDA analogs were characterized using 1H-NMR, and the
1H-NMR data are shown in Text S1. The specific amines used for
the syntheses are also included in the supplementary information.
Determination of pKa values of geldanamycin analogs
The ionization constants of GDA analogs were determined by
recording the pH-dependent chemical shift of methylene protons
alpha to the weakly basic amine, as described previously [43,44].
All NMR solvents and reagents were obtained from Cambridge
Isotope Labs (Andover, MA), unless noted otherwise. Compounds
were dissolved at a 2–3 mg/mL concentration in D2O. pD
measurements in D2O were performed using a MiniLab model
IQ125 pH electrode (Fisher Scientific, Pittsburg, PA). pD was
adjusted using NaOD (40% in D2O) or DCl (20% in D2O).
1H
NMR spectra were recorded at 37uC using a Bruker 400 MHz
NMR and analyzed using the Bruker Topspin software. 4-
Dimethyl-4-silapentane-1-sulfonic acid (DSS) was used as the
reference peak. pD was converted to pH using the following
expression: pH = 0.936pD*+0.412 [45]. The change in chemical
shift of protons alpha to the amine as a function of pH yielded
sigmoidal plots that were fit to a 4-parameter logistic equation
using SigmaPlot (Systat Software, San Jose, CA) from which pKa
was determined. The calculated pKa for compound 7 was
determined using the MarvinSketch version 5.3.8. pKa plugin
(www.chemaxon.com).
Assessment of Hsp90 binding affinity of geldanamycin
analogs
The binding affinity of the weakly basic GDA analogues to
rHsp90 was measured using a previously described competitive
displacement fluorescence polarization assay [46], using GDA
conjugated to FITC (BioMol, Enzo Life Sciences, Plymouth
Meeting, PA) as the fluorescent tracer molecule. Non-binding
surface 96-well plates (Corning) used for the binding experiments
were obtained from Fisher Scientific. A binding buffer composed
of 20 mM Hepes, pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM
Na2MoO4, and 0.01% NP40 was used. Bovine gamma globulin
(0.1 mg/mL) and 1 mM DTT were freshly added to the buffer
before use. GDA-FITC was reconstituted in DMSO at a stock
concentration of 10 mM and was used at a final concentration of
2 nM. The rHsp90 (Enzo Life Sciences) was diluted to a final
concentration of 40 nM. Eight different concentrations of GDA
analogs ranging from 0 to 2000 nM were added to a mixture of
rHsp90 and GDA-FITC in individual wells of a 96-well plate, and
the plates were placed on a shaker in a 4uC refrigerator for 4 h.
Fluorescence polarization measurements were performed using a
Wallac Envision Multilabel plate reader (Perkin Elmer), as
previously described [47]. Plots of fluorescence polarization versus
GDA analog concentration yielded sigmoidal curves that were fit
to 3 or 4 parameter logistic equations from which the IC50 values
were obtained. The IC50 values obtained from the plots were
converted to Ki values as previously described [28].
Generation of MD-MBA-231 cells with elevated lysosomal
pH
MDA-MB-231 cells with elevated lysosomal pH were generated
by lentiviral vector-mediated knockdown of the V-ATPase V1E1
subunit (ATP6V1E1). The lentiviral transfer vector pPGK-Neo-
ATP6V1E1 encoding the target sequence 59-CAGATGTCTC-
CAATTTGATGAAT-39 against the V-ATPase V1E1 subunit
was obtained from Mission (Sigma, St. Louis, MO). The control
cells were treated with a pPGK-Neo transfer vector containing the
sequence 59-CAACAAGATGAAGAGCACCAA-39, which does
not target any known mammalian gene. Lentiviral particles were
produced by transfecting HEK 293T cells with the transfer vector
together with a proprietary lentiviral packaging mix from Sigma,
following the manufacturer’s instructions. For the transfection,
56105 HEK 293T cells were seeded in 10 cm dishes and allowed
to adhere overnight. After the cells adhered, 2.6 mg of vector DNA
was combined with 26 mL of the lentiviral packaging mix and
transfected into cells using Fugene-6 transfection reagent (Roche
Diagnostics, Indianapolis, IN), according to the manufacturer’s
instructions. The transfection complexes were incubated with the
HEK 293T cells overnight and then the media was replaced. The
virus-containing cell culture supernatants were harvested twice:
once at 24 h and again at 48 h. Prior to use, the viral media was
filtered through a 0.45-mm filter and added onto 70% confluent
75 cc flasks of MDA-MB-231 cells, in the presence of 8 mg/mL
hexadimethrine bromide. The viruses were allowed to infect the
cells for 16–18 h, after which the media containing viruses was
replaced with fresh media for a further 24 h prior to analysis of
knockdown of V1E1 expression. The knockdown efficiency was
analyzed by Western blotting, performed as described previously
[22]. A goat polyclonal antibody to the V1E1 subunit (sc-21218;
Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:200
dilution to detect VIE1, and a mouse monoclonal antibody was
used at a 1:10000 dilution to detect actin (loading control). Anti-
goat HRP-conjugated secondary antibody (Santa Cruz Biotech-
nology) was used at a 1:5000 dilution, and anti-mouse HRP-
conjugated secondary antibody was used at a 1:1000 dilution.
Determination of lysosomal pH
Lysosomal pH was determined following a previously a
published protocol [24], with modifications. Briefly, 16105 cells/
well were plated in 8-chamber tissue culture treated microscope
slides (BD Falcon, Bedford, MA) and allowed to adhere overnight.
Cells were incubated with 1 mg/mL Oregon Green 488 dextran
10,000 MW (Invitrogen) for 2 h, followed by 6 h incubation in
dextran-free medium to allow the dextran to specifically localize in
terminal lysosomes. At the end of the chase period, the cells were
rinsed with and maintained in lysosomal pH buffer composed
of150 mM NaCl, 20 mM Mes, 5 mM KCl, and 1 mM MgSO4,
pH 7.4. The emission of Oregon Green 488 at both 495 and
450 nm excitation wavelengths at 525/10 nm emission in the cells
was then measured using a microscope-adapted Ratiomaster
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spectrofluorimeter (PTI, Trenton, NJ) equipped with a photo-
multiplier tube detector. The ratio of emission at 495 nm
excitation to the emission at 450 nm excitation was calculated
and converted into lysosomal pH using a lysosomal pH calibration
curve. To generate the lysosomal pH calibration curve, lysosomal
pH buffers of pH 4, 5, 5.5, and 6 containing 10 mM nigericin and
20 mM monensin were added to respective wells of the 8-chamber
slide for 30 min to equilibrate intracellular pH with extracellular
pH, and the fluorescence emission was measured as described
above. The emission intensity ratios were calculated as described,
and a standard curve was obtained by plotting pH against the
respective 495/450 nm emission ratios. The calibration curve was
linear between pH 4–6.
Antiproliferative evaluations for anticancer agents
Cell sensitivity to compounds was evaluated using the WST-1
(4-[3[(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-ben-
zene disulfonate) assay (BioAssay Systems, Hayward, CA), which
was performed according to the manufacturer’s instructions.
Briefly, 4000 cells were seeded per well of a 96-well plate and
allowed to adhere overnight. Cells were incubated in increasing
concentrations (9 different concentrations ranging from
0.00001 mM to 1000 mM) of drug for a period of 72 h. At the
end of the drug treatment period, 10 mL of WST-1 reagent was
added per well, allowed to incubate at 37uC for 2 hours, and
absorbance at 450 and 620 nm (reference) was measured using a
Multiskan model MCC/340 microplate reader (ThermoElectron
Corp, Hudson, NH). Cell viability as a percent of control
(untreated) cells was plotted against drug concentration to generate
cytotoxicity curves, which were fit to 3 or 4 parameter logistic Hill
plots using SigmaPlot. IC50 values were determined from the curve
fit.
Statistical Analysis
Data presentation and statistical analysis was carried out using
Sigma Plot v10.0 and v12.3 (SPSS, Chicago, IL). Statistical
analyses of significance (p values) were calculated using Students’ t-
tests comparing the selectivity values of the GDA analogs with
those of GDA. Results were considered statistically significant
when p,0.05.
Supporting Information
Figure S1 pH-dependent chemical shifts of protons
adjacent to the amine group of geldanamycin analogs
at 376C. The chemical shifts were plotted against pH and fit to a
3-parameter sigmoidal curve fit (solid line). pKa was determined
from the curve fit.
(TIF)
Figure S2 Competitive inhibition of geldanamycin-FITC
binding to rHsp90 by geldanamycin and analogs.
Competitive inhibition was measured using a fluorescence
polarization assay. Polarization values of drug-treated wells were
converted to percent of control wells (no drug) and plotted against
drug concentration. The curves were fit to 3- or 4-parameter
logistic Hill plots from which the IC50 was determined. The data
points are the mean of duplicate experiments.
(TIF)
Figure S3 Cytotoxicity of geldanamycin and analogs in
normal fibroblasts and in HL60 human leukemic cells.
Cells were exposed to the indicated varying concentrations of
GDA and its analogs for 72 h. The filled circles represent data
acquired from normal fibroblasts and the open circles represent
data from experiments with HL60 cells. The IC50 was determined
from the curve fit using 3- or 4-parameter logistic Hill plots. Data
represent mean6SD (n = 3).
(TIF)
Figure S4 Cytotoxicity of geldanamycin and its analogs
in MDA-MB 231 cells with low and elevated lysosomal
pH. The cells were exposed to the indicated concentrations of
GDA and its analogs for 72 h. The filled circles represent
scrambled shRNA-treated cells with low lysosomal pH and the
open circles represent V1E1 shRNA-treated cells with elevated
lysosomal pH. The IC50 was determined by fitting the curves to 3-
or 4-parameter logistic Hill plots. Data represent mean6SD
(n = 3).
(TIF)
Figure S5 Cytotoxicity of anticancer agents in MDA-MB
231 cells with low and elevated lysosomal pH. The cells
were exposed to indicated concentrations of mitoxantrone,
daunorubicin, 5-fluorouracil and chlorambucil for 72 h. The filled
circles represent data from cells treated with scrambled shRNA
with low lysosomal pH and the open circles represent data from
V1E1 shRNA-treated cells with elevated lysosomal pH. The IC50
was determined by fitting the curves to 3- or 4-parameter logistic
Hill plots. Data represent mean6SD (n = 3).
(TIF)
Text S1 Method of synthesis and 1H-NMR characterization of
geldanamycin analogs. Geldanamycin analogs were synthesized
using Method A or B, as described in Materials and Methods, and
characterized by 1H-NMR.
(DOCX)
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44. Grycová L, Dommisse R, Pieters L, Marek R (2009) NMR determination of
pKa values of indoloquinoline alkaloids. Magn Res Chem 47: 977–981.
45. Krezel A, Bal W (2004) A formula for correlating pKa values determined in
D2O and H2O. J Inorg Biochem 98: 161–166.
46. Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G (2003) Synthesis of novel
fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett
13: 3975–3978.
47. Borrok MJ, Kiessling LL (2007) Non-carbohydrate inhibitors of the lectin DC-
SIGN. J Am Chem Soc 129: 12780–12785.
Influence of pKa on Anticancer Drug Selectivity
PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e49366
